Specific effects of escitalopram on neuroendocrine response |
| |
| Authors: | Emily R. Hawken James A. Owen Robert W. Hudson Nicholas J. Delva |
| |
| Affiliation: | (1) Providence Care Centre-Mental Health Services, Kingston, ON, Canada;(2) Department of Pharmacology and Toxicology, Queen’s University, Kingston, ON, Canada;(3) Department of Psychiatry, Queen’s University, Kingston, ON, K7L 3N6, Canada;(4) Department of Medicine (Endocrinology), Queen’s University, Kingston, ON, Canada;(5) Department of Psychiatry, Dalhousie University, Halifax, NS, Canada; |
| |
| Abstract: | Purpose Citalopram, a selective serotonin reuptake inhibitor, is used as a neuroendocrine probe in human subjects to assess serotonin function as reflected in prolactin and plasma cortisol release. Citalopram is a racemic mixture of equal proportions of the S(+) and R(−) enantiomers. Inhibition of serotonin reuptake and, consequently, antidepressant activity is associated, almost exclusively, with the S(+) enantiomer (“escitalopram”). Studies in animal models indicate that the presence of the R(−) isomer may interfere with the serotonin reuptake activity of escitalopram. The current study compared the neuroendocrine effects of citalopram and escitalopram in healthy human volunteers. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
